E-MEXP-433 - Transcription profiling of human chromic myeloid leukemia (CML) patients treated second-line with imatinib after failure of an interferon-alpha based therapy to identify genes with predictive value for primary cytogenetic outcome to imatinib
Released on 31 May 2006, last updated on 29 July 2015
Identification of genes in CML patients with predictive value for their primary cytogenetic outcome to imatinib. All samples analyzed were taken just before the start of imatinib treatment. Leukemic patients were treated second-line with imatinib after failure of an interferon-alpha based therapy (first-line regimen).
transcription profiling by array, clinical history
Oliver Frank <email@example.com>, Andreas A Hochhaus, Benedikt B Brors, Chun C Zheng, Li L Li, Markus M Haak, Norbert N Gretz, Rodiger R Hehlmann, Sylvia S Merk, Uwe U Schwindel, Wolfgang W Seifarth
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, Schwindel U, Zheng C, Muller MC, Gretz N, Hehlmann R, Hochhaus A, Seifarth W.